[Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome]
- PMID: 18239370
- DOI: 10.1248/yakushi.128.233
[Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome]
Abstract
PEGylated liposomes (approximately 100 nm in diameter) lose their long-circulating characteristic upon repeated injection at certain intervals in the same animal (referred to as the "accelerated blood clearance (ABC) phenomenon"), as described by our group and by researchers in the Netherlands. Recently, it was demonstrated by our group that anti-PEG IgM, induced by the first dose of PEGylated liposomes, is responsible for the ABC phenomenon. The IgM produced in this manner then selectively bound to the surface of subsequently injected PEGylated liposomes, leading to substantial complement activation. It is generally believed that nanocarriers coated with a polymer, such as PEG, have no immunogenicity. However, unexpected immune responses occurred even in response to polymer-coated liposomes. This immunogenicity to PEGylated liposomes presents a serious concern in the development and clinical use of liposomal formulations. In this review, we demonstrate our recent observations regarding with the ABC phenomenon against liposomes.
Similar articles
-
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.Int J Pharm. 2008 Apr 16;354(1-2):56-62. doi: 10.1016/j.ijpharm.2007.11.005. Epub 2007 Nov 9. Int J Pharm. 2008. PMID: 18083313 Review.
-
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.J Control Release. 2007 Jun 4;119(2):236-44. doi: 10.1016/j.jconrel.2007.02.010. Epub 2007 Feb 24. J Control Release. 2007. PMID: 17399838
-
Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.J Control Release. 2006 Oct 27;115(3):243-50. doi: 10.1016/j.jconrel.2006.08.001. Epub 2006 Aug 7. J Control Release. 2006. PMID: 17011060
-
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.J Control Release. 2006 Oct 27;115(3):251-8. doi: 10.1016/j.jconrel.2006.08.017. Epub 2006 Sep 3. J Control Release. 2006. PMID: 17045355
-
[Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].Yao Xue Xue Bao. 2010 Jun;45(6):677-83. Yao Xue Xue Bao. 2010. PMID: 20939173 Review. Chinese.
Cited by
-
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.Chem Rev. 2015 Oct 14;115(19):10530-74. doi: 10.1021/acs.chemrev.5b00321. Epub 2015 Aug 27. Chem Rev. 2015. PMID: 26313138 Free PMC article. Review.
-
Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.PLoS One. 2017 Sep 27;12(9):e0185654. doi: 10.1371/journal.pone.0185654. eCollection 2017. PLoS One. 2017. PMID: 28953936 Free PMC article.
-
Bufalin-Loaded PEGylated Liposomes: Antitumor Efficacy, Acute Toxicity, and Tissue Distribution.Nanoscale Res Lett. 2019 Jul 5;14(1):223. doi: 10.1186/s11671-019-3057-0. Nanoscale Res Lett. 2019. PMID: 31278603 Free PMC article.
-
Liposome-encapsulated EF24-HPβCD inclusion complex: a preformulation study and biodistribution in a rat model.J Nanopart Res. 2011 Jun 1;13(6):2609-2623. doi: 10.1007/s11051-010-0154-5. J Nanopart Res. 2011. PMID: 21779150 Free PMC article.
-
High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.J Control Release. 2021 Oct 10;338:804-812. doi: 10.1016/j.jconrel.2021.08.051. Epub 2021 Sep 2. J Control Release. 2021. PMID: 34481925 Free PMC article.
